BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 275.61

Change

+1.57 (+0.57)%

Market Cap

USD 41.26B

Volume

0.88M

Average Target Price

USD 295.04 (+7.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMGN Amgen Inc

-1.59 (-0.63%)

USD146.06B 21.06 13.23
AZN AstraZeneca PLC

+0.57 (+1.06%)

USD141.08B 35.51 17.04
SNY Sanofi

+0.63 (+1.22%)

USD128.75B 8.80 8.68
GILD Gilead Sciences, Inc

+0.94 (+1.41%)

USD83.45B 277.25 26.35
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
HZNP Horizon Therapeutics Public Li..

-1.69 (-1.92%)

USD19.76B 70.29 31.66
GRFS Grifols, S.A

+0.37 (+2.03%)

USD16.63B 36.57 17.04
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16

ETFs Containing BIIB

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-2.55 (-1.42%)

USD0.53B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.11 (-1.59%)

USD0.35B
FLXG:XETRA Franklin LibertyQ Global .. 0.00 % 0.40 %

+0.15 (+0.49%)

USD0.02B
CEM2:XETRA iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:XETRA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.21 (+0.51%)

USD0.05B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.10 (-1.81%)

USD0.35B
CEM2:F iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:F Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.23 (+0.55%)

USD0.05B
BUYB:PA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.20 (+0.49%)

USD0.06B
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.59 %

+0.07 (+0.67%)

USD0.02B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.10 (-1.41%)

USD0.35B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.13 (-2.61%)

USD0.19B
DQML Reality Shares Fundstrat .. 0.00 % 0.69 %

N/A

USD2.62M
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.97 (-3.60%)

USD0.22B
MXDU Nationwide Maximum Divers.. 0.00 % 0.34 %

-0.27 (-0.70%)

USD0.11B
FFIU Fieldstone UVA Unconstrai.. 0.00 % 0.51 %

-0.03 (-0.13%)

USD0.08B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.35 %

-0.26 (-0.67%)

USD0.14B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PKW Invesco BuyBack Achievers.. 0.00 % 0.62 %

-0.29 (-0.32%)

USD1.84B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.45 %

-0.30 (-0.90%)

USD0.17B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

-2.68 (-1.79%)

USD10.29B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.77 %

-0.65 (-1.70%)

USD0.02B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.76 (+3.38%)

USD0.01B
GMVM:XETRA VanEck Vectors Morningsta.. 0.00 % 0.49 %

+0.14 (+0.32%)

USD0.50B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.56% 63% D 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.56% 63% D 61% D-
Trailing 12 Months  
Capital Gain -15.98% 25% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.98% 13% F 11% F
Trailing 5 Years  
Capital Gain 3.13% 25% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.13% 25% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 0.60% 25% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.60% 13% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 17.77% 50% F 80% B-
Risk Adjusted Return 3.35% 13% F 27% F
Market Capitalization 41.26B 50% F 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.21 88% B+ 61% D-
Price/Book Ratio 3.86 75% C 42% F
Price / Cash Flow Ratio 9.75 88% B+ 40% F
EV/EBITDA 10.19 88% B+ 71% C-
Management Effectiveness  
Return on Equity 26.49% 75% C 92% A-
Return on Invested Capital 18.46% 88% B+ 90% A-
Return on Assets 9.27% 88% B+ 93% A
Debt to Equity Ratio 69.40% 63% D 32% F
Technical Ratios  
Short Ratio 2.98 88% B+ 45% F
Short Percent 2.42% 50% F 60% D-
Beta 0.42 50% F 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.